^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Beta radiation emitter

    Related drugs:
    1d
    Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma (clinicaltrials.gov)
    P2, N=130, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2027 --> Jan 2033 | Trial primary completion date: Jan 2026 --> Jan 2030
    Trial completion date • Trial primary completion date
    |
    NF1 (Neurofibromin 1) • VHL (von Hippel-Lindau tumor suppressor) • SSTR (Somatostatin Receptor)
    |
    RET mutation • VHL mutation
    |
    Lutathera (lutetium Lu 177 dotatate)
    2d
    Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting. (PubMed, Oncol Ther)
    Available therapeutic options include radioligand therapy (e.g. lutetium-177-PSMA-617), cabazitaxel, PARP inhibitors (particularly for patients with DNA repair gene alterations), second-line ARTAs, further chemotherapy and immunotherapeutic approaches. Finally, the review provides an overview of promising emerging therapies poised to expand the treatment landscape for mCRPC. These include bispecific T cell engagers, androgen receptor degraders, and antibody-drug conjugates, which are currently under investigation in clinical trials and may soon offer new avenues for treatment beyond traditional mechanisms.
    Review • Journal • BRCA Biomarker • PARP Biomarker • IO biomarker
    |
    AR (Androgen receptor) • BRCA (Breast cancer early onset) • FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    3d
    Expanding the therapeutic horizon of 177Lu-DOTATATE: a review of current evidence. (PubMed, Nagoya J Med Sci)
    Considering that SSTR expression is also present in various other tumors-including pheochromocytomas, paragangliomas, meningiomas, and medullary thyroid carcinomas-there is increasing interest in expanding the use of PRRT to other SSTR-positive malignancies. This review aimed to present evidence, explore ongoing clinical research, and highlight emerging directions for 177Lu-DOTATATE therapy beyond gastroenteropancreatic NETs.
    Review • Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    5d
    NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake (clinicaltrials.gov)
    P1/2, N=35, Completed, Advanced Accelerator Applications | N=71 --> 35
    Enrollment change • First-in-human
    |
    AAA603
    5d
    MOMENTUM-1: Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment (clinicaltrials.gov)
    P2, N=153, Recruiting, RTOG Foundation, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SSTR2 (Somatostatin Receptor 2)
    |
    Avastin (bevacizumab) • sunitinib • everolimus • hydroxyurea • Lutathera (lutetium Lu 177 dotatate)
    5d
    A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (clinicaltrials.gov)
    P1/2, N=140, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=200 --> 140
    Enrollment closed • Enrollment change
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Lutathera (lutetium Lu 177 dotatate)
    6d
    PSMAndARPI: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=420 --> 7
    Enrollment closed • Enrollment change
    |
    Xtandi (enzalutamide) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    6d
    A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. (clinicaltrials.gov)
    P1, N=65, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Jul 2027
    Enrollment closed • Trial completion date
    |
    temozolomide • Lutathera (lutetium Lu 177 dotatate)
    7d
    177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=61, Recruiting, Radiopharm Theranostics, Ltd | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026
    Enrollment open • Trial initiation date
    7d
    Current and future perspectives on radioligand therapy in advanced prostate cancer. (PubMed, Ther Adv Med Oncol)
    Nonetheless, challenges remain around long-term hematologic and renal safety, radionuclide supply, protocol standardization, and global accessibility. Ongoing and future multicenter trials, collaborative consortia, and innovations in theranostics will be critical to defining optimal patient selection, sequencing with existing therapies, and embedding RLT as a key pillar in the management of advanced PCa.
    Review • Journal
    |
    STEAP1 (STEAP Family Member 1) • KLK2 (Kallikrein-related peptidase 2)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    7d
    Predicting eligibility for outpatient 177Lu-DOTATATE-targeted radionuclide therapy in patients with neuroendocrine tumors. (PubMed, Nucl Med Commun)
    The whole-body washout rate derived from pretreatment SSTR imaging is a strong, practical predictor for outpatient eligibility following 177Lu-DOTATATE TRT. Incorporating this simple, noninvasive marker into clinical workflow could support individualized discharge planning and improve patient access under strict radiation safety regulations.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    7d
    ArTisaN: TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets (clinicaltrials.gov)
    P2, N=24, Completed, Imperial College London | Recruiting --> Completed
    Trial completion
    |
    TheraSphere (yttrium 90 microspheres)